Alexei Zelenev1, Portia Shea2, Alyona Mazhnaya3, Anna Meteliuk4, Iryna Pykalo5, Ruthanne Marcus2, Tatiana Fomenko4, Tatiana Prokhorova4, Frederick L Altice6. 1. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, 06510, USA. Electronic address: alexei.zelenev@yale.edu. 2. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, 06510, USA. 3. ICF Alliance for Public Health in Ukraine, 5 Dilova str. Building 10A, Kyiv 03150, Ukraine; Johns Hopkins Bloomberg School of Public Health, Department of Health, Behavior and Society, 624 N Broadway, Baltimore, MD 21205, USA. 4. ICF Alliance for Public Health in Ukraine, 5 Dilova str. Building 10A, Kyiv 03150, Ukraine. 5. Ukrainian Institute on Public Health Policy, Mala Zhytomyrska St, 5, Kyiv, 01001, Ukraine. 6. Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, CT, 06510, USA; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, New Haven, CT, 06510, USA.
Abstract
BACKGROUND: Ukraine, a country of 45.5 million people, has one of the most volatile HIV and HCV epidemics in the world. In this paper, we estimate the prevalence of HIV and HCV among PWID in five Ukrainian cities. METHODS: A cross-sectional study was conducted in 2014-2015, based on stratified hybrid sampling with random and respondent driven sampling in five cities: Kyiv, Odesa, Mykolaiv, Dnipro and Lviv. Using data on HIV and HCV antibody testing from 1613 respondents, we evaluate selection bias in the sampling methods by analyzing spatial and network patterns of sampling processes. We develop and apply inverse probability weights in order to estimate the HIV and HCV prevalence in each city, as well as in the overall sample. FINDINGS: The aggregate HIV prevalence for the five cities is 35.1% (95% CI: 29.5%-38.5%) but this varied considerably by city: in Kyiv the HIV prevalence is 26.6% (95% CI: 20.3.8%-33.4%), in Odesa - 38.2% (95% CI: 29.8% and 47.1%), in Mykolaiv - 42.0% (95% CI: 34.3%-49.2%), in Dnipro - 58.8% (95% CI: 52.2%-65.8%), and in Lviv 24.6% (95% CI: 18.8%-30.8%). The aggregate HCV prevalence estimate for the five cities is 58.6% (95% CI: 54.9%-61.7%). The highest HCV prevalence is estimated in Kyiv - 84.8% (95% CI: 78.5%-90.1%). HCV prevalence in Odesa is the lowest and estimated to be 36.5% (95% CI: 29.5%-45.1%), in Mykolaiv - 49.1% (95% CI: 41.5%-57.0%), in Dnipro - 56.1% (95% CI: 50.3%-63.4%) and in Lviv 38.5% (95% CI: 31.8%-45.0%). CONCLUSIONS: Monitoring behavioral and health outcomes of PWID on a regular basis is necessary for determining prevention and treatment priorities for HIV and HCV infections in Ukraine and elsewhere. The heterogeneity of the local epidemics provides insights into the best prevention and treatment strategies to be deployed in low-resource settings.
BACKGROUND: Ukraine, a country of 45.5 million people, has one of the most volatile HIV and HCV epidemics in the world. In this paper, we estimate the prevalence of HIV and HCV among PWID in five Ukrainian cities. METHODS: A cross-sectional study was conducted in 2014-2015, based on stratified hybrid sampling with random and respondent driven sampling in five cities: Kyiv, Odesa, Mykolaiv, Dnipro and Lviv. Using data on HIV and HCV antibody testing from 1613 respondents, we evaluate selection bias in the sampling methods by analyzing spatial and network patterns of sampling processes. We develop and apply inverse probability weights in order to estimate the HIV and HCV prevalence in each city, as well as in the overall sample. FINDINGS: The aggregate HIV prevalence for the five cities is 35.1% (95% CI: 29.5%-38.5%) but this varied considerably by city: in Kyiv the HIV prevalence is 26.6% (95% CI: 20.3.8%-33.4%), in Odesa - 38.2% (95% CI: 29.8% and 47.1%), in Mykolaiv - 42.0% (95% CI: 34.3%-49.2%), in Dnipro - 58.8% (95% CI: 52.2%-65.8%), and in Lviv 24.6% (95% CI: 18.8%-30.8%). The aggregate HCV prevalence estimate for the five cities is 58.6% (95% CI: 54.9%-61.7%). The highest HCV prevalence is estimated in Kyiv - 84.8% (95% CI: 78.5%-90.1%). HCV prevalence in Odesa is the lowest and estimated to be 36.5% (95% CI: 29.5%-45.1%), in Mykolaiv - 49.1% (95% CI: 41.5%-57.0%), in Dnipro - 56.1% (95% CI: 50.3%-63.4%) and in Lviv 38.5% (95% CI: 31.8%-45.0%). CONCLUSIONS: Monitoring behavioral and health outcomes of PWID on a regular basis is necessary for determining prevention and treatment priorities for HIV and HCV infections in Ukraine and elsewhere. The heterogeneity of the local epidemics provides insights into the best prevention and treatment strategies to be deployed in low-resource settings.
Authors: Alexander R Bazazi; Forrest Crawford; Alexei Zelenev; Robert Heimer; Adeeba Kamarulzaman; Frederick L Altice Journal: AIDS Behav Date: 2015-12
Authors: Louisa Degenhardt; Bradley M Mathers; Andrea L Wirtz; Daniel Wolfe; Adeeba Kamarulzaman; M Patrizia Carrieri; Steffanie A Strathdee; Kasia Malinowska-Sempruch; Michel Kazatchkine; Chris Beyrer Journal: Int J Drug Policy Date: 2013-09-04
Authors: Alyona Mazhnaya; Anna Meteliuk; Tetiana Barnard; Alexei Zelenev; Sergii Filippovych; Frederick L Altice Journal: Int J Drug Policy Date: 2017-08-12
Authors: Kate Dolan; Andrea L Wirtz; Babak Moazen; Martial Ndeffo-Mbah; Alison Galvani; Stuart A Kinner; Ryan Courtney; Martin McKee; Joseph J Amon; Lisa Maher; Margaret Hellard; Chris Beyrer; Fredrick L Altice Journal: Lancet Date: 2016-07-14 Impact factor: 79.321
Authors: Andrea J Low; Gitau Mburu; Nicky J Welton; Margaret T May; Charlotte F Davies; Clare French; Katy M Turner; Katharine J Looker; Hannah Christensen; Susie McLean; Tim Rhodes; Lucy Platt; Matthew Hickman; Andy Guise; Peter Vickerman Journal: Clin Infect Dis Date: 2016-06-25 Impact factor: 9.079
Authors: Jack Stone; Louisa Degenhardt; Jason Grebely; Sarah Larney; Frederick L Altice; Pavlo Smyrnov; Afarin Rahimi-Movaghar; Maryam Alavi; April M Young; Jennifer R Havens; William C Miller; Matthew Hickman; Peter Vickerman Journal: Lancet Psychiatry Date: 2021-02-25 Impact factor: 27.083
Authors: Anna Yakovleva; Ganna Kovalenko; Matthew Redlinger; Mariia G Liulchuk; Eric Bortz; Viktoria I Zadorozhna; Alla M Scherbinska; Joel O Wertheim; Ian Goodfellow; Luke Meredith; Tetyana I Vasylyeva Journal: Res Sq Date: 2021-11-30
Authors: Anna Yakovleva; Ganna Kovalenko; Matthew Redlinger; Mariia G Liulchuk; Eric Bortz; Viktoria I Zadorozhna; Alla M Scherbinska; Joel O Wertheim; Ian Goodfellow; Luke Meredith; Tetyana I Vasylyeva Journal: Sci Rep Date: 2022-09-21 Impact factor: 4.996
Authors: Adam Trickey; Nadiya Semchuk; Tetiana Saliuk; Yana Sazonova; Olga Varetska; Josephine G Walker; Aaron G Lim; Jack Stone; Peter Vickerman Journal: J Int AIDS Soc Date: 2020-08 Impact factor: 5.396